文献速递免疫规划传染病防控与疫情报告

基孔肯雅疫苗接种接受度:留尼汪岛疫情期间的快速调查

Acceptance of chikungunya vaccination: a rapid survey in Reunion island during an epidemic.
PubMed 文献 · Vaccine · 2025-09-13

2025年留尼汪岛基孔肯雅疫情暴发初期,一项横断面网络调查收集918份完整回复,评估居民疫苗接种接受度。假设全额报销场景下接受度最高(60.5%),临床试验和自费场景分别降至35.5%和20.1%。女性和既往基孔肯雅感染者接受度较低,医护人员更可能接种,合并症无显著关联。

要点

  • 全额报销场景下接种接受度为60.5%,自费场景降至20.1%。
  • 女性及既往基孔肯雅感染者接种接受度较低,医护人员更可能接受。
  • 合并症与接种接受度无显著关联,支付方式与实施背景是关键驱动因素。

核心结论

  • 在2025年疫情暴发初期,支付方式和实施背景以及性别差异是接种意愿的关键驱动因素。

研究设计与样本

  • 2025年1月开展的横断面网络调查,获得918份完整回复,平均年龄44.5岁,13.1%有既往基孔肯雅病史,53.4%为医护人员。

主要发现

  • 假设全额报销场景下接种接受度为60.5%,假设临床试验场景为35.5%,假设自费场景为20.1%。
  • 女性和有既往基孔肯雅病史者接种接受度较低,医护人员更可能接受接种。
  • 合并症与接种接受度无显著关联。

关键数值与推荐

  • 全额报销场景接受度60.5%,临床试验场景接受度35.5%,自费场景接受度20.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During the 2025 chikungunya outbreak in Réunion Island, two vaccines-IXCHIQ (live-attenuated) and VIMKUNYA (virus-like particle)-received European Union authorization; a local campaign began in April 2025 and was temporarily adjusted for older adults after safety concerns. We assessed vaccine acceptability at the outbreak onset among residents, focusing on people with comorbidities. In January 2025, a cross-sectional web survey yielded 918 complete responses (mean age 44.5 years; 13.1 % prior chikungunya; 53.4 % healthcare workers). Acceptability was highest in the hypothetical full-reimbursement scenario (60.5 %) and was lower among women and those with prior chikungunya; healthcare workers were more likely to accept vaccination. In the hypothetical clinical-trial and self-financed scenarios, acceptability declined to 35.5 % and 20.1 %, respectively, with the same pattern of predictors. Comorbidities showed no significant association. Financing and implementation context, together with gender differences, were key drivers of uptake at the beginning of 2025 outbreak.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Manaquin R, Desmoulin A, Luong Nguyen LB, et al. Acceptance of chikungunya vaccination: a rapid survey in Reunion island during an epidemic. Vaccine. 2025. PMID: 40946352. doi:10.1016/j.vaccine.2025.127720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。